Results from the PRIMA Trial: Comparison of the STHLM3 Test and Prostate-specific Antigen in General Practice for Detection of Prostate Cancer in a Biopsy-naive Population

Article Medicine, General & Internal

Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only

Jonas Hugosson et al.

Summary: MRI-directed targeted biopsy for prostate cancer screening reduces the risk of overdiagnosis by half compared to systematic biopsy, but may delay the detection of intermediate-risk tumors in a small proportion of patients.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Economics

Cost-Effectiveness Analysis of Stockholm 3 Testing Compared to PSA as the Primary Blood Test in the Prostate Cancer Diagnostic Pathway: A Decision Tree Approach

Bettina Wulff Risor et al.

Summary: This study evaluated the cost effectiveness of using STHLM3 testing compared to the PSA test in the diagnostic pathway for prostate cancer. The results showed that STHLM3 testing was more effective but also more costly than the PSA test. The results were sensitive to the cost of the STHLM3 test, indicating that a lower cost would improve its cost effectiveness compared to PSA tests.

APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2022)

Add to Collection

Article Urology & Nephrology

Prostate Cancer Detection Rate of Manually Operated and Robot-assisted In-bore Magnetic Resonance Imaging Targeted Biopsy

Mads Sandahl et al.

Summary: This study compared the detection rates (DRs) of prostate cancer (PC) between manually operated in-bore magnetic resonance imaging (MRI) targeted prostate biopsy (MO-MRGB) and robot-assisted in-bore MRI targeted prostate biopsy (RA-MRGB). The results showed no significant difference in PC detection ability between the two systems.

EUROPEAN UROLOGY OPEN SCIENCE (2022)

Add to Collection

Article Urology & Nephrology

Clinical Utility of 4Kscore®, ExosomeDx™ and Magnetic Resonance Imaging for the Early Detection of High Grade Prostate Cancer

Claire M. de la Calle et al.

Summary: Screening algorithms with upfront liquid biomarker testing followed by multiparametric magnetic resonance imaging and biopsy at certain biomarker thresholds could reduce unnecessary biopsies, multiparametric magnetic resonance imaging, and the overdetection of Gleason grade 1 prostate cancer.

JOURNAL OF UROLOGY (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Review Urology & Nephrology

EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

Nicolas Mottet et al.

Summary: The 2020 EAU-EANM-ESTRO-ESUR-SIOG guidelines on screening, diagnosis, and treatment of localized prostate cancer summarize the most recent recommendations for clinical practice, including risk-adapted strategies, medical imaging utilization, biopsy techniques, patient classification, and treatment options. Recommendations include consideration of moderate hypofractionation for intermediate-risk patients and a combination of local treatment with long-term hormonal therapy for cN1 PCa patients.

EUROPEAN UROLOGY (2021)

Add to Collection

Article Oncology

Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial

Tobias Nordstrom et al.

Summary: This study compared traditional screening methods for prostate cancer with a diagnostic strategy combining blood-based risk prediction and MRI-targeted biopsies. The use of the Stockholm3 test was found to be non-inferior to PSA for the detection of clinically significant prostate cancer, while also detecting a similar number of low-grade cancers. Additionally, the combination of Stockholm3 with MRI-targeted biopsies led to higher detection rates of significant cancers and lower rates of low-grade cancers compared to standard screening methods.

LANCET ONCOLOGY (2021)

Add to Collection

Review Oncology

Prostate Cancer Liquid Biopsy Biomarkers' Clinical Utility in Diagnosis and Prognosis

Milena Matuszczak et al.

Summary: In prostate cancer, overdiagnosis and overtreatment are common problems. New liquid biopsy biomarker tests have been developed to improve diagnosis, prognosis, and decision-making. The current gold standard for diagnosing prostate cancer relies on digital rectal examination and elevated prostate-specific antigen levels before biopsy.

CANCERS (2021)

Add to Collection

Article Medicine, General & Internal